VIDEO: Dual immunotherapy outperforms monotherapy in metastatic colorectal cancer
In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.
The randomized study compared combination immunotherapy with nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) vs. nivolumab alone in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Results showed combination immunotherapy outperformed monotherapy in 36-month PFS (68% vs. 51%), as well as in objective response rate (71% vs. 58%). At median follow-up of 47 months, patients treated with the combination immunotherapy had a 38% reduction in risk for disease or death.
“We don’t have OS data yet with the dual immune checkpoint, but there’s definitely more toxicity too, so this is, I think, a decision on a case-by-case basis with the patients,” Cecchini, associate professor of medical oncology at Yale School of Medicine, said. “Informed decision-making here is key and critical.”
Reference:
- Andre T, et al. Abstract LBA143. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse